Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Long-Term Investments (2020 - 2026)

Amphastar Pharmaceuticals has reported Long-Term Investments over the past 6 years, most recently at $14.5 million for Q4 2025.

  • For Q4 2025, Long-Term Investments rose 31.87% year-over-year to $14.5 million; the TTM value through Dec 2025 reached $14.5 million, up 31.87%, while the annual FY2025 figure was $14.5 million, 31.87% up from the prior year.
  • Long-Term Investments for Q4 2025 was $14.5 million at Amphastar Pharmaceuticals, up from $13.3 million in the prior quarter.
  • Over five years, Long-Term Investments peaked at $14.5 million in Q4 2025 and troughed at $527000.0 in Q4 2023.
  • A 5-year average of $6.2 million and a median of $4.7 million in 2022 define the central range for Long-Term Investments.
  • Biggest five-year swings in Long-Term Investments: crashed 88.29% in 2023 and later soared 1986.53% in 2024.
  • Year by year, Long-Term Investments stood at $3.4 million in 2021, then surged by 32.35% to $4.5 million in 2022, then crashed by 88.29% to $527000.0 in 2023, then soared by 1986.53% to $11.0 million in 2024, then skyrocketed by 31.87% to $14.5 million in 2025.
  • Business Quant data shows Long-Term Investments for AMPH at $14.5 million in Q4 2025, $13.3 million in Q3 2025, and $12.1 million in Q2 2025.